Form 8-K - Current report:
SEC Accession No. 0001193125-24-201295
Filing Date
2024-08-15
Accepted
2024-08-15 16:02:00
Documents
17
Period of Report
2024-07-26
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d878992d8k.htm   iXBRL 8-K 31820
2 EX-99.1 d878992dex991.htm EX-99.1 671456
6 GRAPHIC g878992dsp015.jpg GRAPHIC 433299
7 GRAPHIC g878992dsp016.jpg GRAPHIC 411298
8 GRAPHIC g878992dsp017.jpg GRAPHIC 243049
  Complete submission text file 0001193125-24-201295.txt   2356254

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA phasq-20240726.xsd EX-101.SCH 2514
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE phasq-20240726_lab.xml EX-101.LAB 18503
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE phasq-20240726_pre.xml EX-101.PRE 11627
20 EXTRACTED XBRL INSTANCE DOCUMENT d878992d8k_htm.xml XML 3809
Mailing Address 1 GREAT VALLEY PARKWAY SUITE 30 MALVERN PA 19355
Business Address 1 GREAT VALLEY PARKWAY SUITE 30 MALVERN PA 19355 (610) 981-6500
PhaseBio Pharmaceuticals Inc (Filer) CIK: 0001169245 (see all company filings)

EIN.: 030375697 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38697 | Film No.: 241212314
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)